Clinical Trial Update: An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 exploratory study is evaluating the safety and efficacy of anti-CD19/BCMA U CAR-T cells for relapsed/refractory immune-mediated kidney disease,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Kidney Disease
• Immune-mediated Nephropathy

Drugs mentioned

• anti-CD19/BCMA U CAR-T cells

Snippet

Sponsor: Changhai Hospital | Conditions: Relapsed/Refractory Immune Nephropathy, Relapsed/Refractory Immune-mediated Kidney Disease | EARLY_Phase 1 | Status: RECRUITING